BUZZ-<a href="https://laohu8.com/S/LYRA">Lyra Therapeutics</a> plunges after halting development of lead nasal drug** Shares of drug developer Lyra Therapeutics LYRA.O plummet 39% to $2.28 premarket
** LYRA says it will stop developing its lead drug LYR-210 for chronic rhinosinusitis, an inflammation of the nasal passages and sinuses
** Says it will cut most of its workforce; retain CEO and CFO as consultants
** SSG Capital Advisors engaged to explore strategic alternatives - LYRA
** Move comes after co reported positive late-stage trial data for LYR-210 in June that drove shares up over 300%
** LYRA had $22.1 million in cash as of September 30, and expects remaining funds to last into Q3 2026
** Stock fell 71.5% in 2025
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.